2026-04-17T00:43:43Zhttps://recercat.cat/oai/request

oai:recercat.cat:2072/4713652025-09-22T06:55:54Zcom_2072_98col_2072_378192

00925njm 22002777a 4500 dc Rudolph, Tanka K. author Messika-Zeitoun, David author Frey, Norbert author Thambyrajah, Jeetendra author Serra, Antonio author Schulz, Eberhard author Maly, Jiri author Aiello, Marco author Lloyd, Guy author Bortone, Alessandro Santo author Clerici, Alberto author Delle-Karth, Georg author Rieber, Johannes author Indolfi, Ciro author Mancone, Massimo author Belle, Loic author Lauten, Alexander author Arnold, Martin author Bouma, Berto J. author Lutz, Matthias author Deutsch, Cornelia author Kurucova, Jana author Thoenes, Martin author Bramlage, Peter author Steeds, Richard author Universitat Autònoma de Barcelona author 2020 Contemporary data regarding the impact of comorbidities on the clinical presentation and management of patients with severe aortic stenosis (AS) are scarce. Prospective registry of severe patients with AS across 23 centres in nine European countries. Of the 2171 patients, chronic kidney disease (CKD 27.3%), left ventricular ejection fraction (LVEF) <50% (22.0%), atrial fibrillation (15.9%) and chronic obstructive pulmonary disease (11.4%) were the most prevalent comorbidities (49.3% none, 33.9% one and 16.8% ≥2 of these). The decision to perform aortic valve replacement (AVR) was taken in a comparable proportion (67%, 72% and 69%, in patients with 0, 1 and ≥2 comorbidities; p=0.186). However, the decision for TAVI was more common with more comorbidities (35.4%, 54.0% and 57.0% for no, 1 and ≥2; p<0.001), while the decision for surgical AVR (SAVR) was decreased with increasing comorbidity burden (31.9%, 17.4% and 12.3%; p<0.001). The proportion of patients with planned AVRs that were performed within 3 months was significantly higher in patients with 1 or ≥2 comorbidities than in those without (8.7%, 10.0% and 15.7%; p<0.001). Furthermore, the mean time to AVR was significantly shorter in patients with one (30.5 days) or ≥2 comorbidities (30.8 days) than in those without (35.7 days; p=0.012). Patients with reduced LVEF tended to be offered an AVR more frequently and with a shorter delay while patients with CKD were less frequently treated. Comorbidities in severe patients with AS affect the presentation and management of patients with severe AS. TAVI was offered more often than SAVR and performed within a shorter time period. Aortic valve disease Cardiac surgery Prosthetic heart valves Impact of selected comorbidities on the presentation and management of aortic stenosis